𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Preclinical characterization of LY2886721: A BACE1 inhibitor in clinical development for early Alzheimer's disease

✍ Scribed by Patrick May; Leonard Boggs; Richard Brier; David Calligaro; Martin Citron; Theresa Day; Suizhen Lin; Terry Lindstrom; Dustin Mergott; Scott Monk; Manuel Vicente Sanchez-Felix; Scott Sheehan; Grant Vaught; Zhixiang Yang; James Audia


Book ID
118468204
Publisher
Elsevier Science
Year
2012
Tongue
English
Weight
59 KB
Volume
8
Category
Article
ISSN
1552-5260

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Boom in the development of non-peptidic
✍ Romano Silvestri πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 623 KB

## Abstract β‐Amyloid cleaving enzyme‐1 (BACE1) has become a significant target for the therapy of Alzheimer's disease. After the discovery of the first non‐peptidomimetic β‐secretase inhibitors by Takeda Chemicals in 2001, several research teams focused on SAR development of these agents. The non‐